Neurogene (NGNE)
NASDAQ:NGNE
NGNE Stock Chart & Stats
$20.35
-$0.86(-3.93%)
At close: 4:00 PM EST
$20.35
-$0.86(-3.93%)
Day’s Range― - ―
52-Week Range$6.88 - $37.27
Previous CloseN/A
Volume20.02K
Average Volume (3M)225.72K
Market Cap
$316.94M
Enterprise Value$222.98M
Total Cash (Recent Filing)$269.01M
Total Debt (Recent Filing)$9.89M
Price to Earnings (P/E)―
Beta2.95
Next Earnings
May 08, 2026EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding15,574,293
10 Day Avg. Volume272,921
30 Day Avg. Volume225,725
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-283.33
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
$91.50Price Target Upside349.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Trial EnrollmentFull enrollment of the EMBOLDEN registrational study and ongoing dosing progress reflect strong clinical execution and sustained clinician and patient interest that support near-term data readouts.
Regulatory Support And DesignationsBreakthrough Therapy and regenerative medicine designations, combined with FDA alignment on pivotal trial design and procedural advantages, improve the pathway toward accelerated review and potential approval.
Safety Profile At Commercial DoseAbsence of hemophagocytic lymphohistiocytosis events at the selected commercial dose across studies strengthens the safety narrative and reduces a key approval and commercialization risk.
Bears Say
Cash Runway And Financing RiskSustained net losses and relatively high cash burn raise the likelihood of additional financing before commercialization, which could dilute existing shareholders or shift management focus.
Historic High-dose Safety EventA prior fatal inflammatory event in a high-dose cohort remains a material safety overhang that could trigger further protocol changes or heightened regulatory scrutiny.
Regulatory Uncertainty And Efficacy AttributionRegulatory precedent of late changes to requirements and concerns that improvements in very young patients may reflect natural development rather than treatment effect could complicate approval discussions and labeling decisions.
Neurogene News
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $6.88 and its highest was $37.27 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $316.94M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is May 08, 2026 which is in 40 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Mar 24, 2026. The company reported -$1.12 earnings per share for the quarter, beating the consensus estimate of -$1.239 by $0.119.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.35.
How many shares outstanding does Neurogene have?
Neurogene has 15,574,293 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.12 in its last earnings report, beating expectations of -$1.239. Following the earnings report the stock price went up 7.955%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.50 (349.63% Upside)
$91.50 (349.63% Upside)
Insider Transactions
Sold Shares
Worth $84.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 16.1%
Last 30 Days ▲ 37.4%
Last 30 Days ▲ 37.4%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.14%
12-Months-Change
Fundamentals
Return on Equity
-42.25%
Trailing 12-Months
Asset Growth
65.34%
Trailing 12-Months
Company Description
Neurogene
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$91.50
▲(349.63% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―